摘要
乳腺癌是目前全球范围内最常见的恶性肿瘤之一。内分泌治疗是激素受体(HR)阳性乳腺癌重要的治疗方式,治疗药物主要分为绝经前使用的雌激素受体拮抗剂和绝经后使用的芳香化酶抑制剂等,但耐药问题是目前乳腺癌内分泌治疗的重大挑战。该文从基因调控、雌激素与共调辅助因子、生长因子信号通路、细胞周期调控机制、自噬与凋亡机制、非编码RNA调控、免疫监视等方面对绝经前后乳腺癌内分泌治疗的耐药机制和最新的研究结果进行综述,以期为临床解决乳腺癌内分泌治疗耐药问题提供新的依据。
Breast cancer is the most common malignant tumor in the world.Endocrine therapy is an important treatment for HR positive breast cancer,and its drugs are mainly divided into premenopausal estrogen receptor antagonists and postmenopausal aromatase inhibitors,but drug resistance has become a major challenge in endocrine therapy for breast cancer.This article reviews the drug resistance mechanism and the latest research results of endocrine therapy in premenopausal and postmenopausal breast cancer from the aspects of gene regulation,estrogen and coregulatory cofactor,growth factor signal pathway,cell cycle regulation,autophagy and apoptosis,non-coding RNA regulation,immune surveillance,etc.,in order to provide a new basis for clinical solution of endocrine therapy resistance in breast cancer.
作者
阿迪莱·艾萨
赵菁
袁瑛
Adilai Aisa;Zhao Jing;Yuan Ying(Department of Medical Oncology,Key Laboratory of Cancer Prevention and Intervention of Ministry of Education,the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China)
出处
《解放军医学杂志》
CAS
CSCD
北大核心
2021年第7期702-709,共8页
Medical Journal of Chinese People's Liberation Army
基金
国家自然科学基金(81872481)。
关键词
乳腺癌
内分泌治疗耐药
雌激素受体
breast cancer
endocrine therapy resistant
estrogen receptor
